Showing results (51-60 of 85) with videos related to
Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupThomas Büchner, Wolfgang E Berdel, Claudia Haferlach, et al.Haematologica|April 5, 2011
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trialMatthias Stelljes, Dietrich W Beelen, Jan Braess, et al.Plos One|January 10, 2013
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot studyUtz Krug, Anja Koschmieder, Daniela Schwammbach, et al.Blood|July 21, 2012
High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Bernhard Heilmeier, Katrin E Edmaier, et al.Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2006
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemiaThomas Büchner, Wolfgang E Berdel, Claudia Schoch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative GroupThomas Büchner, Wolfgang Hiddemann, Wolfgang E Berdel, et al.Haematologica|June 13, 2012
RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genesPhilipp A Greif, Nikola P Konstandin, Klaus H Metzeler, et al.Blood|November 16, 2012
DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor bindingTill Schoofs, Christian Rohde, Katja Hebestreit, et al.Blood|August 22, 2008
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Manuela Hummel, Clara D Bloomfield, et al.Pageof 9